Cordis Looks To Regain Previous Innovation Edge With Drug-Eluting Balloons
Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.
You may also be interested in...
Cardinal Agrees To Sell Cordis For $1Bn To Hellman & Friedman
Cardinal said it remains “committed to its medical distribution and global medical products businesses” despite the divesture of Cordis.
INTERVIEW: The bigger value picture behind Cardinal Health's Cordis buy
When Johnson & Johnson agreed to sell Cordis to Cardinal Health for nearly $2bn last month, many saw Cardinal Health taking on a portfolio of mature medical devices – albeit of a well-established and globally recognized brand – that did not offer that much differentiation from the competition. So what’s in it for Cardinal Health and what’s the overriding objective behind the move? Tina Tan speaks to Don Casey, CEO of Cardinal Health’s Medical Segment, who spent nearly 26 years at J&J, to find out more about the underlying market changes and the strategy that motivated the company to make not only this particular acquisition, but likely more similar deals in the future
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.